A nurse administers RhoGAM to an Rh-negative client after delivery of an Rh-positive newborn based on the understanding that this drug will prevent her from:

Choice A rationale RhoGAM (Rh Immune Globulin) is designed to neutralize Rh-positive fetal red blood cells that enter the maternal circulation, preventing the mother from developing anti-D antibodies. It does not influence the production of AB antigens, which are part of the separate ABO blood group system and are genetically determined. Choice B rationale RhoGAM contains anti-D antibodies that bind to any Rh-positive fetal red blood cells that may have crossed the placenta into the Rh-negative mother's bloodstream. This masks or destroys the fetal cells, preventing the mother's immune system from recognizing them and initiating its own primary immune response and subsequent Rh alloimmunization or sensitivity. Choice C rationale A person's Rh status is determined by their genetic makeup (presence or absence of the D antigen on red blood cells) and cannot be changed from Rh-negative to Rh-positive by administering a passive antibody preparation like RhoGAM. The drug temporarily suppresses the immune response, it doesn't alter the genotype. Choice D rationale RhoGAM acts to prevent Rh sensitization in the current Rh-negative mother. It has no effect on the mother's ability to become pregnant with a future fetus who may inherit an Rh-positive status from the father, as fertility and fetal inheritance are independent biological processes.